Xenografting of human blood malignancies to immunodeficient SCID mice is a powerful research tool. We evaluate here whether the immunodeficient turkey embryo can also serve as a xenograft host for human blood malignancies. Human leukemia, lymphoma and myeloma lines engrafted robustly into medullary and extramedullary tissues of turkey embryos as detected by PCR, FACS and histology in 8-10 days. Four of eleven patient AML samples also engrafted the bone marrow. Grafts of two lines responded to chemotherapy with doxorubicin. The turkey embryo therefore has the potential to be a complementary xenograft model for the study of human blood malignancies.
|Number of pages||10|
|State||Published - Oct 2009|
Bibliographical noteFunding Information:
Thanks to Tsvee Lapidot for providing the G2 cells, to Ada Refaeli for providing the HL-60 line and Galit Granot for the HBL-2 cells. Thanks to Chaya Morgenstern, Dr. Sigi Kay and Shoshana Baron for excellent technical and administrative assistance. Undergraduate interns Alexandra Polsky and Karen Levi provided invaluable assistance. This research was supported by grants by the Horowitz Foundation for Applied Biomedical Research to R.S.G. and the Israel Ministry of Health (Weinkselbaum family medical research fund), the Israel Cancer Association through a donation from Don and Donna Sherman and Caesaria Edmond Benjamin de Rothchild Foundation (V.R.D.). None of the granting agencies participated in any aspect of the study.
- Chemotherapy testing
- Chick embryo